MAPT and Alzheimer disease: The comparison between the AD and non-AD groups in cohort 1 and 3 (Supplementary Fig. 4) shows significantly higher levels of blood-based BD-tau in the AD group (p < 0.001 in both cohorts) in agreement to previously reported results and similar to CSF T-tau23.